Apremilast (Otezla) for Psoriatic Arthritis

被引：0
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2014年 / 56卷 / 1443期
关键词：
CONTROLLED-TRIAL; EFFICACY; MODERATE;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：41 / 42
页数：2
相关论文
共 9 条
  • [1] [Anonymous], 2013, Med Lett Drugs Ther, V55, pe44
  • [2] [Anonymous], 2013, TREAT GUIDEL MED LET, V11, P1
  • [3] [Anonymous], 2014, MED LETT DRUGS THER, V56, P9
  • [4] Approximate wholesale acquisition cost (WAC), 2014, APPR WHOL ACQ COST W
  • [5] Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
    Kavanaugh, Arthur
    Mease, Philip J.
    Gomez-Reino, Juan J.
    Adebajo, Adewale O.
    Wollenhaupt, Juergen
    Gladman, Dafna D.
    Lespessailles, Eric
    Hall, Stephen
    Hochfeld, Marla
    Hu, ChiaChi
    Hough, Douglas
    Stevens, Randall M.
    Schett, Georg
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (06) : 1020 - 1026
  • [6] Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
    Mease, Philip J.
    Armstrong, April W.
    [J]. DRUGS, 2014, 74 (04) : 423 - 441
  • [7] Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
    Papp, K. A.
    Kaufmann, R.
    Thaci, D.
    Hu, C.
    Sutherland, D.
    Rohane, P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (03) : e376 - e383
  • [8] Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
    Papp, Kim
    Cather, Jennifer C.
    Rosoph, Les
    Sofen, Howard
    Langley, Richard G.
    Matheson, Robert T.
    Hu, ChiaChi
    Day, Robert M.
    [J]. LANCET, 2012, 380 (9843) : 738 - 746
  • [9] Strand V, 2013, HEALTH QUAL LIFE OUT, V10, P11
1